Mustang Bio Inc. (NASDAQ:MBIO) went up by 1.47% from its latest closing price compared to the recent 1-year high of $4.85. The company’s stock price has collected -1.78% of loss in the last five trading sessions. Press Release reported on 10/26/20 that Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer
Is It Worth Investing in Mustang Bio Inc. (NASDAQ :MBIO) Right Now?
Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for Mustang Bio Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $9.00. MBIO currently public float of 41.80M and currently shorts hold a 5.31% ratio of that float. Today, the average trading volume of MBIO was 1.52M shares.
MBIO’s Market Performance
MBIO stocks went down by -1.78% for the week, with a monthly drop of -12.66% and a quarterly performance of -8.91%, while its annual performance rate touched 1.85%. The volatility ratio for the week stands at 11.26% while the volatility levels for the past 30 days are set at 7.41% for Mustang Bio Inc.. The simple moving average for the period of the last 20 days is -11.72% for MBIO stocks with a simple moving average of -14.46% for the last 200 days.
Analysts’ Opinion of MBIO
Many brokerage firms have already submitted their reports for MBIO stocks, with B. Riley FBR repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to B. Riley FBR is $9 based on the research report published on October 02nd of the current year 2020.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $7. The rating they have provided for MBIO stocks is “Overweight” according to the report published on November 20th, 2019.
H.C. Wainwright gave a rating of “Buy” to MBIO, setting the target price at $7 in the report published on August 13th of the previous year.
MBIO Trading at -15.55% from the 50-Day Moving Average
After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.09% of loss for the given period.
Volatility was left at 7.41%, however, over the last 30 days, the volatility rate increased by 11.26%, as shares sank -12.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.69% lower at present.
During the last 5 trading sessions, MBIO fell by -1.78%, which changed the moving average for the period of 200-days by -30.65% in comparison to the 20-day moving average, which settled at $3.11. In addition, Mustang Bio Inc. saw -32.35% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at MBIO starting from Litchman Manuel MD, who purchase 153,846 shares at the price of $3.25 back on Jun 11. After this action, Litchman Manuel MD now owns 488,846 shares of Mustang Bio Inc., valued at $500,000 using the latest closing price.
Litchman Manuel MD, the President and CEO of Mustang Bio Inc., purchase 90,000 shares at $3.13 during a trade that took place back on May 21, which means that Litchman Manuel MD is holding 335,000 shares at $281,700 based on the most recent closing price.
Stock Fundamentals for MBIO
The total capital return value is set at -88.60, while invested capital returns managed to touch -90.90. Equity return is now at value -91.50, with -65.50 for asset returns.
Based on Mustang Bio Inc. (MBIO), the company’s capital structure generated 30.06 points at debt to equity in total, while total debt to capital is 23.12. Total debt to assets is 21.14, with long-term debt to equity ratio resting at 27.15. Finally, the long-term debt to capital ratio is 20.87.
The liquidity ratio also appears to be rather interesting for investors as it stands at 8.12.
Jeff Brown is a tech investor known for his incredible success rate. In fact, he’s invested in 111 different tech startups… and made money on 95.3% of them.
Like Intabio, which developed a groundbreaking system to test biopharmaceuticals.
As of today, he estimates his investment is up 25,000%. He made 743% in three days on InfoSpace!
And now, he’s just released the details on his number one tech stock for 2019.